Disc Medicine presents positive Phase 1b data for DISC-0974 in CKD anemia at ASN Kidney Week

Disc Medicine, Inc.

Dose-dependent hepcidin reduction >75% from baseline at highest dose (60 mg); transferrin saturation up to 3x baseline.
Mean hemoglobin increase of +0.55 g/dL at 60 mg vs +0.21 g/dL placebo; individual max increase +1.8 g/dL.
All treatment-related adverse events Grade 1 or 2; majority unrelated to DISC-0974; acceptable safety profile.
Data from SAD cohorts (28, 40, 60 mg) in Stage 2-5 NDD-CKD anemia; dose escalation and multiple-dose portion ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.